Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas

Abstract

Triptolide (TP) shows strong anti-tumor activities on various cancer cells, especially on pancreatic cancer. TP inhibits HSP70 expression leading to cell death in pancreatic cancer cells and induces cell death by apoptotic and autophagic pathways. In order to increase the therapeutic index of TP, a novel intravenous TP-loaded delivery system, TP-loaded lipid emulsion (TP-LE), has been developed to treat solid tumor. In the present study, the preparation and characterization of TP-LE were described. The pharmacokinetics and tissue distribution study of TP-LE in mice were also evaluated. Results demonstrated that TP-LE had an average particle size of 154.6 nm, entrapment efficiency (EE%) of 87%, zeta potential of À0.903 mV and autoclaved stability. The pharmacokinetic study showed that blood concentrations of both TP-LE and TP reached a maximum at the end of intravenous administration (1.25 mg/kg) and declined rapidly within the first 10 min with a mean residence time (MRT) of about 10 min. In the tissue distribution study, a preferential accumulation and longer residence time of drug in pancreas were found in TP-LE. The AUC 0-60min of TP-LE in pancreas was 2.19 times in comparison to free TP, suggesting that the use of TP-LE conferred improvements in biodistribution, accumulation and therapeutic efficacy in pancreas. Moreover, the concentrations of TP-LE in heart, lung and kidney were lower than that of the TP group, indicating the potential for reduced toxicity of TP-LE. Together, all the results show that TP-LE appears to be a promising formulation for using TP in treating cancer, and more specifically pancreatic cancer.

Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies

“…The data were analyzed according to the previous papers (Li et al, 2016 ; Rezazadeh et al, 2016 ). For each group, the concentration-time curve was profiled according to the mean concentration of 6 mice for a point.…”

TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment

“…Recently, TP has attracted immense attention to its anticancer activity with multiple mechanisms, which can reduce drug resistance for cancers [8][9][10][11]. Several studies have shown that TP is more effective against pancreatic cancer compared with gemcitabine, paclitaxel, cisplatin and doxorubicin [12][13][14]. However, its clinical development has been greatly hampered by its poor water solubility (0.017 mg/mL) [15], multi-organ toxicity [16][17][18] and low bioavailability.…”

Transdermal delivery of triptolide–phospholipid complex to treat rheumatoid arthritis

“…RA affects about 1% of the population, and it is associated with a large number of medical resources (Feldmann, 2002 ; Malahias et al, 2012 ; Yang et al, 2017 ). Triptolide, a diterpene epoxide, exhibits diverse pharmacological activities, including antirheumatic, analgesic, anti-inflammatory, immunosuppressive, and antitumor activities (Liu, 2011 ; Li et al, 2016 ). It has also been shown to be very effective against many autoimmune and inflammatory diseases, especially RA (Fan et al, 2018 ).…”